Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

* Inclusion Criteria: * The following criteria apply to ALL patients starting the study treatment: * Patients with histologically confirmed, locally advanced or metastatic solid tumors refractory to standard therapy or in whom regorafenib is considered a standard treatment. * Male or Female Caucasian patients \>/= 18 years of age * Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration. * Life expectancy of at leat 12 weeks * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate bone marrow and liver function * Estimated creatinine clearance (CLcr) ≥ 30 mL/min as calculated using the Cockroft-Gault (C-G) equation. * Thyroid Stimulating Hormone(TSH) within normal ranges. * The following inclusion criteria apply to Group A (digoxin + regorafenib) patients ONLY: * Potassium, magnesium and calcium blood levels within normal range according to the local laboratory. * The following inclusion criteria apply to Group B (rosuvastatin + regorafenib) patients ONLY: * Signed genetic informed consent. Patients must be able to understand and willing to sign the written informed consent intended to screen for BCRP and OATP1B1 polymorphisms. * Exclusion Criteria: * For ALL patients * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication. * Non-healing wound, skin ulcer, or bone fracture. * Ongoing or active infection. * Other anticancer treatment. * Patients unable to swallow oral medications * For Group A (digoxin + regorafenib): * Family history of sudden cardiac death. * For Group B (rosuvastatin + regorafenib): * Patients with porphyria. * Patients with intestinal or urinary obstructions.